TWST insider filing: Dennis Cho awarded 25,465 RSUs of common stock

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) officer Dennis Cho reported a grant of 25,465 restricted stock units (RSUs) of common stock at a price of $0 per share. After this equity award, he beneficially owns 146,159 shares of Twist Bioscience common stock in total.

The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, subject to his continuous service with the company. Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and this Form 4 reflects routine insider equity compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cho Dennis

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,465	$0.00	--

Holdings After Transaction: Common Stock — 146,159 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		A		25,465(1)	A	$0	146,159	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Twist Bioscience (TWST) report on this Form 4?

The filing reports that Dennis Cho, an officer of Twist Bioscience, received a grant of 25,465 restricted stock units (RSUs) of the companys common stock at a price of $0 per share.

What is the vesting schedule for Dennis Cho19s 25,465 RSUs at Twist Bioscience (TWST)?

The 25,465 RSUs vest so that 1/16 of the total vests on each quarterly anniversary of November 20, 2025, resulting in a 48-month total vesting period, subject to his continuous service.

How many Twist Bioscience (TWST) shares does Dennis Cho own after this RSU grant?

Following the reported transaction, Dennis Cho beneficially owns 146,159 shares of Twist Bioscience common stock.

What is Dennis Cho19s role at Twist Bioscience (TWST)?

Dennis Cho is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience.

Does this Form 4 for Twist Bioscience (TWST) involve derivative securities?

The provided section of the Form 4 includes no reported transactions in derivative securities in Table II; the reported transaction involves restricted stock units in Table I.

On what date was the earliest reportable transaction for this Twist Bioscience (TWST) Form 4?

The date of the earliest transaction reported is November 18, 2025.